{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:10Z","timestamp":1792704010186,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T00:00:00Z","timestamp":1412812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/nrc3829","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T14:40:39Z","timestamp":1412692839000},"page":"754-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1393,"title":["Cancer cachexia: understanding the molecular basis"],"prefix":"10.1038","volume":"14","author":[{"given":"Josep M.","family":"Argil\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Busquets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Stemmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez-Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"key":"BFnrc3829_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans, W. J. et al. Cachexia: a new definition. Clin. Nutr. 27, 793\u2013799 (2008).","journal-title":"Clin. Nutr."},{"key":"BFnrc3829_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u2013495 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrc3829_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jamda.2010.02.004","volume":"11","author":"JM Argil\u00e9s","year":"2010","unstructured":"Argil\u00e9s, J. M. et al. Consensus on cachexia definitions. J. Am. Med. Dir. Assoc. 11, 229\u2013230 (2010).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"BFnrc3829_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/00000441-193211000-00002","volume":"184","author":"S Warren","year":"1932","unstructured":"Warren, S. The inmediate cause of death in cancer. Am. J. Med. Sci. 184, 610\u2013613 (1932).","journal-title":"Am. J. Med. Sci."},{"key":"BFnrc3829_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","volume":"69","author":"WD Dewys","year":"1980","unstructured":"Dewys, W. D. et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69, 491\u2013497 (1980).","journal-title":"Am. J. Med."},{"key":"BFnrc3829_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","volume":"34","author":"SCCM Teunissen","year":"2007","unstructured":"Teunissen, S. C. C. M. et al. Symptom prevalence in patients with incurable cancer: a systematic review. J. Pain Symptom Manage. 34, 94\u2013104 (2007).","journal-title":"J. Pain Symptom Manage."},{"key":"BFnrc3829_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/annonc\/mdu086","volume":"25","author":"D Blum","year":"2014","unstructured":"Blum, D. et al. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model\u2014a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25, 1635\u20131642 (2014).","journal-title":"Ann. Oncol."},{"key":"BFnrc3829_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00520-009-0800-6","volume":"18","author":"D Blum","year":"2010","unstructured":"Blum, D. et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer 18, 273\u2013279 (2010).","journal-title":"Support Care Cancer"},{"key":"BFnrc3829_CR9","doi-asserted-by":"crossref","unstructured":"Bozzetti, F. & Mariani, L. Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN. J. Parenter. Enteral Nutr. 33, 361\u2013367.","DOI":"10.1177\/0148607108325076"},{"key":"BFnrc3829_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jand.2013.09.027","volume":"114","author":"AL Vigano","year":"2014","unstructured":"Vigano, A. L. et al. The Abridged Patient-Generated Subjective Global Assessment Is a Useful Tool for Early Detection and Characterization of Cancer Cachexia. J. Acad. Nutr. Diet. 114, 1088\u20131098 (2014).","journal-title":"J. Acad. Nutr. Diet."},{"key":"BFnrc3829_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13539-011-0027-5","volume":"2","author":"JM Argil\u00e9s","year":"2011","unstructured":"Argil\u00e9s, J. M. et al. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J. Cachexia. Sarcopenia Muscle 2, 87\u201393 (2011).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"BFnrc3829_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13539-013-0123-9","volume":"4","author":"S Busquets","year":"2013","unstructured":"Busquets, S. et al. Staging cachectic cancer patients using the cachexia score (CASCO). Communication 3-03. Abstracts of the 7th cachexia conference, kobe\/osaka, Japan, december 9\u201311, 2013. J. Cachexia. Sarcopenia Muscle 4, 295\u2013343 (2013).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"BFnrc3829_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/SPC.0b013e328319d7fa","volume":"2","author":"MJ Tisdale","year":"2008","unstructured":"Tisdale, M. J. Catabolic mediators of cancer cachexia. Curr. Opin. Support. Palliat. Care 2, 256\u2013261 (2008).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"BFnrc3829_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/SPC.0b013e3283311d09","volume":"3","author":"JM Argil\u00e9s","year":"2009","unstructured":"Argil\u00e9s, J. M., Busquets, S., Toledo, M. & L\u00f3pez-Soriano, F. J. The role of cytokines in cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 263\u2013268 (2009).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"BFnrc3829_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clnu.2011.07.010","volume":"31","author":"C Scheede-Bergdahl","year":"2012","unstructured":"Scheede-Bergdahl, C. et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin. Nutr. 31, 85\u201388 (2012).","journal-title":"Clin. Nutr."},{"key":"BFnrc3829_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF03256436","volume":"16","author":"T Punzi","year":"2012","unstructured":"Punzi, T. et al. C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol. Diagn. Ther. 16, 115\u2013124 (2012).","journal-title":"Mol. Diagn. Ther."},{"key":"BFnrc3829_CR17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00109-007-0220-3","volume":"85","author":"M-A Weber","year":"2007","unstructured":"Weber, M.-A. et al. Myoglobin plasma level related to muscle mass and fiber composition: a clinical marker of muscle wasting? J. Mol. Med. 85, 887\u2013896 (2007).","journal-title":"J. Mol. Med."},{"key":"BFnrc3829_CR18","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.2741\/2293","volume":"12","author":"JM Argil\u00e9s","year":"2007","unstructured":"Argil\u00e9s, J. M. et al. Targets in clinical oncology: the metabolic environment of the patient. Front. Biosci. 12, 3024\u20133051 (2007).","journal-title":"Front. Biosci."},{"key":"BFnrc3829_CR19","first-page":"3347","volume":"45","author":"WK Evans","year":"1985","unstructured":"Evans, W. K. et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 45, 3347\u20133353 (1985).","journal-title":"Cancer Res."},{"key":"BFnrc3829_CR20","first-page":"15","volume":"27","author":"C Constantinou","year":"2011","unstructured":"Constantinou, C. et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27, 15\u201324 (2011).","journal-title":"Int. J. Mol. Med."},{"key":"BFnrc3829_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2004.03.021","volume":"212","author":"PM Sanders","year":"2004","unstructured":"Sanders, P. M. & Tisdale, M. J. Effect of zinc-\u03b12-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett. 212, 71\u201381 (2004).","journal-title":"Cancer Lett."},{"key":"BFnrc3829_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.febslet.2004.12.050","volume":"579","author":"S Busquets","year":"2005","unstructured":"Busquets, S. et al. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett. 579, 717\u2013722 (2005).","journal-title":"FEBS Lett."},{"key":"BFnrc3829_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/sj.bjc.6600074","volume":"86","author":"P Collins","year":"2002","unstructured":"Collins, P., Bing, C., McCulloch, P. & Williams, G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br. J. Cancer 86, 372\u2013375 (2002).","journal-title":"Br. J. Cancer"},{"key":"BFnrc3829_CR24","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3892\/ijo.2013.1998","volume":"43","author":"AA Tzika","year":"2013","unstructured":"Tzika, A. A. et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int. J. Oncol. 43, 886\u2013894 (2013).","journal-title":"Int. J. Oncol."},{"key":"BFnrc3829_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bbalip.2014.03.004","volume":"1841","author":"D Antunes","year":"2014","unstructured":"Antunes, D. et al. Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting. Biochim. Biophys. Acta 1841, 896\u2013905 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrc3829_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1113\/expphysiol.2013.072496","volume":"98","author":"C Fermoselle","year":"2013","unstructured":"Fermoselle, C. et al. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice. Exp. Physiol. 98, 1349\u20131365 (2013).","journal-title":"Exp. Physiol."},{"key":"BFnrc3829_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.18632\/aging.100436","volume":"4","author":"AM Shum","year":"2012","unstructured":"Shum, A. M. et al. Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY) 4, 133\u2013143 (2012).","journal-title":"Aging (Albany NY)"},{"key":"BFnrc3829_CR28","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.biocel.2013.04.014","volume":"45","author":"AI Padr\u00e3o","year":"2013","unstructured":"Padr\u00e3o, A. I. et al. Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. Int. J. Biochem. Cell Biol. 45, 1399\u20131409 (2013).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrc3829_CR29","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1158\/0008-5472.CAN-07-0231","volume":"67","author":"G Fuster","year":"2007","unstructured":"Fuster, G. et al. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of \u03b22-adrenergic agonists. Cancer Res. 67, 6512\u20136519 (2007).","journal-title":"Cancer Res."},{"key":"BFnrc3829_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.exger.2013.08.004","volume":"48","author":"C Kang","year":"2013","unstructured":"Kang, C., Chung, E., Diffee, G. & Ji, L. L. Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: role of PGC-1\u03b1. Exp. Gerontol. 48, 1343\u20131350 (2013).","journal-title":"Exp. Gerontol."},{"key":"BFnrc3829_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S1097-2765(01)00390-2","volume":"8","author":"P Puigserver","year":"2001","unstructured":"Puigserver, P. et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPAR\u03b3 coactivator-1. Mol. Cell 8, 971\u2013982 (2001).","journal-title":"Mol. Cell"},{"key":"BFnrc3829_CR32","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2353\/ajpath.2006.060034","volume":"169","author":"S Miura","year":"2006","unstructured":"Miura, S. et al. Overexpression of peroxisome proliferator-activated receptor \u03b3 co-activator-1\u03b1 leads to muscle atrophy with depletion of ATP. Am. J. Pathol. 169, 1129\u20131139 (2006).","journal-title":"Am. J. Pathol."},{"key":"BFnrc3829_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1139\/H09-044","volume":"34","author":"RT Dirksen","year":"2009","unstructured":"Dirksen, R. T. Sarcoplasmic reticulum-mitochondrial through-space coupling in skeletal muscle. Appl. Physiol. Nutr. Metab. 34, 389\u2013395 (2009).","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"BFnrc3829_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/JES.0b013e3181911fa4","volume":"37","author":"AE Rossi","year":"2009","unstructured":"Rossi, A. E., Boncompagni, S. & Dirksen, R. T. Sarcoplasmic reticulum-mitochondrial symbiosis: bidirectional signaling in skeletal muscle. Exerc. Sport Sci. Rev. 37, 29\u201335 (2009).","journal-title":"Exerc. Sport Sci. Rev."},{"key":"BFnrc3829_CR35","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.bbagen.2012.11.009","volume":"1830","author":"CC Fontes-Oliveira","year":"2013","unstructured":"Fontes-Oliveira, C. C. et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency? Biochim. Biophys. Acta 1830, 2770\u20132778 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrc3829_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1139\/H09-049","volume":"34","author":"A Zorzano","year":"2009","unstructured":"Zorzano, A. Regulation of mitofusin-2 expression in skeletal muscle. Appl. Physiol. Nutr. Metab. 34, 433\u2013439 (2009).","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"BFnrc3829_CR37","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1002\/ijc.26298","volume":"130","author":"PF Cosper","year":"2012","unstructured":"Cosper, P. F. & Leinwand, L. A. Myosin heavy chain is not selectively decreased in murine cancer cachexia. Int. J. Cancer 130, 2722\u20132727 (2012).","journal-title":"Int. J. Cancer"},{"key":"BFnrc3829_CR38","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539\u20131547 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3829_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon, K., Arends, J. & Baracos, V. Understanding the mechanisms and treatment options in cancer cachexia. Nature Rev. Clin. Oncol. 10, 90\u201399 (2013).","journal-title":"Nature Rev. Clin. Oncol."},{"key":"BFnrc3829_CR40","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/0026-0495(95)90040-3","volume":"44","author":"T Le Bricon","year":"1995","unstructured":"Le Bricon, T., Gugins, S., Cynober, L. & Baracos, V. E. Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44, 1340\u20131348 (1995).","journal-title":"Metabolism."},{"key":"BFnrc3829_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-6147(96)10021-3","volume":"17","author":"JM Argil\u00e9s","year":"1996","unstructured":"Argil\u00e9s, J. M. & L\u00f3pez-Soriano, F. J. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol. Sci. 17, 223\u2013226 (1996).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrc3829_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/bbrc.2001.5849","volume":"290","author":"P-O Hasselgren","year":"2002","unstructured":"Hasselgren, P.-O., Wray, C. & Mammen, J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem. Biophys. Res. Commun. 290, 1\u201310 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc3829_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/mus.21893","volume":"43","author":"IJ Smith","year":"2011","unstructured":"Smith, I. J. et al. Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. Muscle Nerve 43, 410\u2013414 (2011).","journal-title":"Muscle Nerve"},{"key":"BFnrc3829_CR44","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3945\/ajcn.113.063859","volume":"98","author":"N Tardif","year":"2013","unstructured":"Tardif, N., Klaude, M., Lundell, L., Thorell, A. & Rooyackers, O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am. J. Clin. Nutr. 98, 1485\u20131492 (2013).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrc3829_CR45","doi-asserted-by":"publisher","first-page":"E969","DOI":"10.1152\/ajpendo.00126.2005","volume":"289","author":"BJ Krawiec","year":"2005","unstructured":"Krawiec, B. J., Frost, R. A., Vary, T. C., Jefferson, L. S. & Lang, C. H. Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am. J. Physiol. Endocrinol. Metab. 289, E969\u2013E980 (2005).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrc3829_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.cmet.2007.11.001","volume":"6","author":"C Mammucari","year":"2007","unstructured":"Mammucari, C. et al. FOXO3 controls autophagy in skeletal muscle in vivo. Cell. Metab. 6, 458\u2013471 (2007).","journal-title":"Cell. Metab."},{"key":"BFnrc3829_CR47","doi-asserted-by":"crossref","unstructured":"Egerman, M. A. & Glass, D. J. Signaling pathways controlling skeletal muscle mass. Crit. Rev. Biochem. Mol. Biol. 49, 59\u201368.","DOI":"10.3109\/10409238.2013.857291"},{"key":"BFnrc3829_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","volume":"13","author":"DJ Glass","year":"2010","unstructured":"Glass, D. J. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13, 225\u2013229 (2010).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrc3829_CR49","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cmet.2007.09.009","volume":"6","author":"BA Clarke","year":"2007","unstructured":"Clarke, B. A. et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell. Metab. 6, 376\u2013385 (2007).","journal-title":"Cell. Metab."},{"key":"BFnrc3829_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1083\/jcb.200901052","volume":"185","author":"S Cohen","year":"2009","unstructured":"Cohen, S. et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083\u20131095 (2009).","journal-title":"J. Cell Biol."},{"key":"BFnrc3829_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai, D. et al. IKK\u03b2\/NF-\u03baB activation causes severe muscle wasting in mice. Cell 119, 285\u2013298 (2004).","journal-title":"Cell"},{"key":"BFnrc3829_CR52","first-page":"1239","volume":"30","author":"R Moore-Carrasco","year":"2007","unstructured":"Moore-Carrasco, R. et al. The AP-1\/NF-\u03baB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int. J. Oncol. 30, 1239\u20131245 (2007).","journal-title":"Int. J. Oncol."},{"key":"BFnrc3829_CR53","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1172\/JCI68523","volume":"123","author":"WA He","year":"2013","unstructured":"He, W. A. et al. NF-\u03baB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123, 4821\u20134835 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrc3829_CR54","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ncb1101-1009","volume":"3","author":"C Rommel","year":"2001","unstructured":"Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K\/AKT\/mTOR and PI(3)K\/AKT\/GSK3 pathways. Nature Cell Biol. 3, 1009\u20131013 (2001).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3829_CR55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","volume":"117","author":"M Sandri","year":"2004","unstructured":"Sandri, M. et al. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399\u2013412 (2004).","journal-title":"Cell"},{"key":"BFnrc3829_CR56","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.drudis.2012.02.001","volume":"17","author":"JM Argil\u00e9s","year":"2012","unstructured":"Argil\u00e9s, J. M., Orp\u00ed, M., Busquets, S. & L\u00f3pez-Soriano, F. J. Myostatin: more than just a regulator of muscle mass. Drug Discov. Today 17, 702\u2013709 (2012).","journal-title":"Drug Discov. Today"},{"key":"BFnrc3829_CR57","first-page":"408","volume":"4","author":"K Hitachi","year":"2013","unstructured":"Hitachi, K. & Tsuchida, K. Role of microRNAs in skeletal muscle hypertrophy. Front. Physiol. 4, 408 (2013).","journal-title":"Front. Physiol."},{"key":"BFnrc3829_CR58","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1073\/pnas.1402714111","volume":"111","author":"WA He","year":"2014","unstructured":"He, W. A. et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl Acad. Sci. USA 111, 4525\u20134529 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3829_CR59","doi-asserted-by":"publisher","first-page":"E267","DOI":"10.1152\/ajpendo.00249.2013","volume":"306","author":"A Kulyt\u00e9","year":"2014","unstructured":"Kulyt\u00e9, A. et al. MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 306, E267\u2013E274 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrc3829_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/med.20010","volume":"25","author":"JM Argil\u00e9s","year":"2005","unstructured":"Argil\u00e9s, J. M., L\u00f3pez-Soriano, J., Almendro, V., Busquets, S. & L\u00f3pez-Soriano, F. J. Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med. Res. Rev. 25, 49\u201365 (2005).","journal-title":"Med. Res. Rev."},{"key":"BFnrc3829_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5493\/wjem.v3.i3.26","volume":"3","author":"M Dalamaga","year":"2013","unstructured":"Dalamaga, M. Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications. World J. Exp. Med. 3, 26\u201333 (2013).","journal-title":"World J. Exp. Med."},{"key":"BFnrc3829_CR62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/SPC.0b013e3282f34738","volume":"1","author":"JM Argil\u00e9s","year":"2007","unstructured":"Argil\u00e9s, J. M., L\u00f3pez-Soriano, F. J. & Busquets, S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr. Opin. Support. Pal. Care. 1, 293\u2013298 (2007).","journal-title":"Curr. Opin. Support. Pal. Care."},{"key":"BFnrc3829_CR63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1126\/science.1198973","volume":"333","author":"SK Das","year":"2011","unstructured":"Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333, 233\u2013238 (2011).","journal-title":"Science."},{"key":"BFnrc3829_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13539-011-0030-x","volume":"2","author":"NA Stephens","year":"2011","unstructured":"Stephens, N. A. et al. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle 2, 111\u2013117 (2011).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"BFnrc3829_CR65","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","volume":"20","author":"M Petruzzelli","year":"2014","unstructured":"Petruzzelli, M. et al. A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell. Metab. 20, 433\u2013447 (2014).","journal-title":"Cell. Metab."},{"key":"BFnrc3829_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513, 100\u2013104 (2014).","journal-title":"Nature."},{"key":"BFnrc3829_CR67","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-11-3536","volume":"72","author":"M Tsoli","year":"2012","unstructured":"Tsoli, M. et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 72, 4372\u20134382 (2012).","journal-title":"Cancer Res."},{"key":"BFnrc3829_CR68","first-page":"2405","volume":"60","author":"C Bing","year":"2000","unstructured":"Bing, C. et al. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res. 60, 2405\u20132410 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc3829_CR69","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1056\/NEJMoa0808949","volume":"360","author":"KA Virtanen","year":"2009","unstructured":"Virtanen, K. A. et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360, 1518\u20131525 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3829_CR70","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-013-2611-8","volume":"41","author":"M Bauwens","year":"2014","unstructured":"Bauwens, M. et al. Molecular imaging of brown adipose tissue in health and disease. Eur. J. Nucl. Med. Mol. Imaging 41, 776\u2013791 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrc3829_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1615\/CritRevOncog.v17.i3.30","volume":"17","author":"JM Argiles","year":"2012","unstructured":"Argiles, J. M., Lopez-Soriano, F. J. & Busquets, S. Counteracting inflammation: a promising therapy in cachexia. Crit. Rev. Oncog. 17, 253\u2013262 (2012).","journal-title":"Crit. Rev. Oncog."},{"key":"BFnrc3829_CR72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/SPC.0000000000000017","volume":"7","author":"GL Klein","year":"2013","unstructured":"Klein, G. L., Petschow, B. W., Shaw, A. L. & Weaver, E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr. Opin. Support. Palliat. Care 7, 361\u2013367 (2013).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"BFnrc3829_CR73","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/fon.10.20","volume":"6","author":"MJ Tisdale","year":"2010","unstructured":"Tisdale, M. J. Are tumoral factors responsible for host tissue wasting in cancer cachexia? Future Oncol. 6, 503\u2013513 (2010).","journal-title":"Future Oncol."},{"key":"BFnrc3829_CR74","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1096\/fj.13-245894","volume":"28","author":"JL Chen","year":"2014","unstructured":"Chen, J. L. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711\u20131723 (2014).","journal-title":"FASEB J."},{"key":"BFnrc3829_CR75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1042\/BJ20112024","volume":"446","author":"S Lokireddy","year":"2012","unstructured":"Lokireddy, S. et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem. J. 446, 23\u201336 (2012).","journal-title":"Biochem. J."},{"key":"BFnrc3829_CR76","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531\u2013543 (2010).","journal-title":"Cell"},{"key":"BFnrc3829_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","volume":"3","author":"S Busquets","year":"2012","unstructured":"Busquets, S. et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle 3, 37\u201343 (2012).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"BFnrc3829_CR78","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1096\/fj.13-230375","volume":"27","author":"TP Braun","year":"2013","unstructured":"Braun, T. P. et al. Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. 27, 3572\u20133582 (2013).","journal-title":"FASEB J."},{"key":"BFnrc3829_CR79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/SPC.0b013e32833e4aa5","volume":"4","author":"A Molfino","year":"2010","unstructured":"Molfino, A., Laviano, A. & Rossi Fanelli, F. Contribution of anorexia to tissue wasting in cachexia. Curr. Opin. Support Palliat Care 4, 249\u2013253 (2010).","journal-title":"Curr. Opin. Support Palliat Care"},{"key":"BFnrc3829_CR80","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s00520-014-2215-2","volume":"22","author":"J McGreevy","year":"2014","unstructured":"McGreevy, J. et al. Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer. Support. Care Cancer 22, 2635\u20132644 (2014).","journal-title":"Support. Care Cancer"},{"key":"BFnrc3829_CR81","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/01.mco.0000134363.53782.cb","volume":"7","author":"EJB Ramos","year":"2004","unstructured":"Ramos, E. J. B. et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr. Opin. Clin. Nutr. Metab. Care 7, 427\u2013434 (2004).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrc3829_CR82","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","volume":"48","author":"H Suzuki","year":"2013","unstructured":"Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N. & Inui, A. Cancer cachexia\u2014pathophysiology and management. J. Gastroenterol. 48, 574\u2013594 (2013).","journal-title":"J. Gastroenterol."},{"key":"BFnrc3829_CR83","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MCO.0b013e3283455d45","volume":"14","author":"CMM Prado","year":"2011","unstructured":"Prado, C. M. M., Antoun, S., Sawyer, M. B. & Baracos, V. E. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Clin. Nutr. Metab. Care 14, 250\u2013254 (2011).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrc3829_CR84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpainsymman.2012.06.020","volume":"46","author":"R Oberholzer","year":"2013","unstructured":"Oberholzer, R. et al. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J. Pain Symptom Manage. 46, 77\u201395 (2013).","journal-title":"J. Pain Symptom Manage."},{"key":"BFnrc3829_CR85","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.peptides.2006.11.021","volume":"28","author":"MA Joppa","year":"2007","unstructured":"Joppa, M. A., Gogas, K. R., Foster, A. C. & Markison, S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28, 636\u2013642 (2007).","journal-title":"Peptides"},{"key":"BFnrc3829_CR86","doi-asserted-by":"publisher","first-page":"F1315","DOI":"10.1152\/ajprenal.00341.2012","volume":"303","author":"WW Cheung","year":"2012","unstructured":"Cheung, W. W. & Mak, R. H. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease. Am. J. Physiol. Renal Physiol. 303, F1315\u2013F1324 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrc3829_CR87","doi-asserted-by":"publisher","first-page":"e37971","DOI":"10.1371\/journal.pone.0037971","volume":"7","author":"LB Bindels","year":"2012","unstructured":"Bindels, L. B. et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS ONE 7, e37971 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrc3829_CR88","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.biocel.2013.06.021","volume":"45","author":"LB Bindels","year":"2013","unstructured":"Bindels, L. B. & Delzenne, N. M. Muscle wasting: the gut microbiota as a new therapeutic target? Int. J. Biochem. Cell Biol. 45, 2186\u20132190 (2013).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrc3829_CR89","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature04330","volume":"439","author":"M Watanabe","year":"2006","unstructured":"Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484\u2013489 (2006).","journal-title":"Nature"},{"key":"BFnrc3829_CR90","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12031-007-0004-9","volume":"33","author":"HS Wang","year":"2007","unstructured":"Wang, H. S., Oh, D. S., Ohning, G. V. & Pisegna, J. R. Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors. J. Mol. Neurosci. 33, 225\u2013231 (2007).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrc3829_CR91","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.3748\/wjg.14.3633","volume":"14","author":"M Kerem","year":"2008","unstructured":"Kerem, M. et al. Adipokines and ghrelin in gastric cancer cachexia. World J. Gastroenterol. 14, 3633\u20133641 (2008).","journal-title":"World J. Gastroenterol."},{"key":"BFnrc3829_CR92","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10147-008-0856-1","volume":"14","author":"M Takahashi","year":"2009","unstructured":"Takahashi, M. et al. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int. J. Clin. Oncol. 14, 315\u2013320 (2009).","journal-title":"Int. J. Clin. Oncol."},{"key":"BFnrc3829_CR93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2009.02.006","volume":"66","author":"EM Karapanagiotou","year":"2009","unstructured":"Karapanagiotou, E. M. et al. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer 66, 393\u2013398 (2009).","journal-title":"Lung Cancer"},{"key":"BFnrc3829_CR94","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.mce.2011.12.021","volume":"351","author":"S Sheriff","year":"2012","unstructured":"Sheriff, S. et al. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol. Cell. Endocrinol. 351, 286\u2013295 (2012).","journal-title":"Mol. Cell. Endocrinol."},{"key":"BFnrc3829_CR95","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/MCO.0000000000000049","volume":"17","author":"S Reano","year":"2014","unstructured":"Reano, S., Graziani, A. & Filigheddu, N. Acylated and unacylated ghrelin administration to blunt muscle wasting. Curr. Opin. Clin. Nutr. Metab. Care 17, 236\u2013240 (2014).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrc3829_CR96","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/apha.12263","volume":"211","author":"AP Yu","year":"2014","unstructured":"Yu, A. P. et al. Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle. Acta Physiol. 211, 201\u2013213 (2014).","journal-title":"Acta Physiol."},{"key":"BFnrc3829_CR97","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/fon.09.136","volume":"6","author":"CS Roxburgh","year":"2010","unstructured":"Roxburgh, C. S. & McMillan, D. C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Futur. Oncol. 6, 149\u2013163 (2010).","journal-title":"Futur. Oncol."},{"key":"BFnrc3829_CR98","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor, M. J. et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer 104, 726\u2013734 (2011).","journal-title":"Br. J. Cancer"},{"key":"BFnrc3829_CR99","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2010.08.012","volume":"54","author":"JF Dumas","year":"2011","unstructured":"Dumas, J. F. et al. Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis. J. Hepatol. 54, 320\u2013327 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrc3829_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","volume":"13","author":"T Eschenhagen","year":"2011","unstructured":"Eschenhagen, T. et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 13, 1\u201310 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrc3829_CR101","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1743-7075-9-76","volume":"9","author":"M Olivan","year":"2012","unstructured":"Olivan, M. et al. Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutr. Metab. 9, 76 (2012).","journal-title":"Nutr. Metab."},{"key":"BFnrc3829_CR102","first-page":"347","volume":"37","author":"M Tian","year":"2010","unstructured":"Tian, M. et al. Cardiac alterations in cancer-induced cachexia in mice. Int. J. Oncol. 37, 347\u2013353 (2010).","journal-title":"Int. J. Oncol."},{"key":"BFnrc3829_CR103","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0022-4804(90)90112-F","volume":"49","author":"C Drott","year":"1990","unstructured":"Drott, C. & Lundholm, K. Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. J. Surg. Res. 49, 62\u201368 (1990).","journal-title":"J. Surg. Res."},{"key":"BFnrc3829_CR104","doi-asserted-by":"publisher","first-page":"e20424","DOI":"10.1371\/journal.pone.0020424","volume":"6","author":"C M\u00fchlfeld","year":"2011","unstructured":"M\u00fchlfeld, C. et al. Cancer induces cardiomyocyte remodeling and hypoinnervation in the left ventricle of the mouse heart. PLoS ONE. 6, e20424 (2011).","journal-title":"PLoS ONE."},{"key":"BFnrc3829_CR105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0277-5379(91)90050-N","volume":"27","author":"A Hyltander","year":"1991","unstructured":"Hyltander, A., Drott, C., K\u00f6rner, U., Sandstr\u00f6m, R. & Lundholm, K. Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer. 27, 9\u201315 (1991).","journal-title":"Eur. J. Cancer."},{"key":"BFnrc3829_CR106","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/SPC.0000000000000016","volume":"7","author":"EA Isenring","year":"2013","unstructured":"Isenring, E. A. & Teleni, L. Nutritional counseling and nutritional supplements: a cornerstone of multidisciplinary cancer care for cachectic patients. Curr. Opin. Support. Palliat. Care 7, 390\u2013395 (2013).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"BFnrc3829_CR107","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fon.14.14","volume":"10","author":"DC Currow","year":"2014","unstructured":"Currow, D. C. & Abernethy, A. P. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 10, 789\u2013802 (2014).","journal-title":"Future Oncol."},{"key":"BFnrc3829_CR108","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/SPC.0000000000000015","volume":"7","author":"JT Dalton","year":"2013","unstructured":"Dalton, J. T., Taylor, R. P., Mohler, M. L. & Steiner, M. S. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr. Opin. Support. Palliat. Care 7, 345\u2013351 (2013).","journal-title":"Curr. Opin. Support. Palliat. Care"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc3829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3829","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:39:15Z","timestamp":1684467555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc3829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,9]]},"references-count":108,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["BFnrc3829"],"URL":"https:\/\/doi.org\/10.1038\/nrc3829","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,9]]},"assertion":[{"value":"9 October 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.A.: Companies' Advisor 2003- Board of Advisors, Danone Research 2005- Board of Advisors, ANECA (National Agency for Evaluation of University Professors); also, on a non-regular basis, an advisor for: Novartis (Switzerland), Par Pharmaceuticals (USA), Sacoor Medical Group (UK), Amgen (USA) and Merck, Sharp and Dohme (USA), Abbott Pharmaceuticals (USA). S.B., B.S. and F.J.L.-S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}